Moreover, these clinical data, which do not specify any oncogenic mutation, and our invasion experiments using some lung cancer cells with different mutation including KRAS (A549), EGFR (H1650), and EML4-ALK (H2228) (Figure 3D) imply that the target therapy for COPS5 may be applicable to the lung cancer patients even with different mutation types. This evidence concerns the gene EGFR and lung carcinoma.